Welcome to our dedicated page for Teleflex SEC filings (Ticker: TFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading about the UroLift system’s market adoption or tracking how Teleflex segments perform in vascular access and anesthesia often means wading through hundreds of pages of SEC prose. Teleflex SEC filings explained simply is exactly what Stock Titan delivers.
Pain point: Clinical-stage disclosures, FDA milestones, and multi-segment revenue notes make Teleflex’s 10-K and 10-Q uniquely dense. Finding risk factors tied to product recalls or pinpointing R&D outlays can take hours.
Solution: Our AI engine highlights every key figure, from catheter sales growth to UroLift reimbursement trends, inside each Teleflex annual report 10-K simplified and Teleflex quarterly earnings report 10-Q filing. Real-time alerts flag Teleflex 8-K material events explained—think FDA clearances or supply-chain updates—minutes after they hit EDGAR.
- Instant dashboards for Teleflex insider trading Form 4 transactions and Teleflex executive stock transactions Form 4
- Segment breakouts and cash-flow trends via AI-powered summaries
- One-click access to the Teleflex proxy statement executive compensation discussion
Need speed? Teleflex Form 4 insider transactions real-time arrive on your screen seconds after filing. Need depth? Our narrative layer connects catheter demand shifts to margin swings, giving you a concise Teleflex earnings report filing analysis.
Whether you’re understanding Teleflex SEC documents with AI for competitive intel or just want a cleaner view of cash-to-capex ratios, Stock Titan replaces the scrolling with insight. No more digging through PDFs—just the disclosures that move the medical-device market.
Teleflex (TFX) reported a sharp swing to loss on non-cash charges. For the quarter ended September 28, 2025, net revenues were $913,021, up from $764,375 a year ago, reflecting contributions from the newly acquired Vascular Intervention business. However, the company posted a net loss of $(408,892), driven primarily by a $403,925 goodwill impairment in Interventional Urology and a $100,000 impairment tied to Titan SGS.
Operating trends were mixed: gross profit rose to $451,642, but higher SG&A and R&D, plus restructuring and separation costs, pressured results. Year‑to‑date, revenue reached $2,394,579 while net loss was $(191,310). Teleflex closed the BIOTRONIK Vascular Intervention acquisition for €704.3 million ($825.2 million) and financed it with a $700 million delayed draw term loan and additional revolver borrowings. Total borrowings increased to $2,681,250, and cash from operations was $188,971 year‑to‑date as investing cash outflows reflected the acquisition.
The company is advancing plans to separate NewCo, with $32,144 in year‑to‑date separation costs. Shares outstanding were 44,194,408 as of November 4, 2025.
Teleflex Incorporated (TFX) furnished an earnings press release and slide presentation announcing results for the quarter ended September 28, 2025. The materials were provided under Items 2.02 and 7.01.
The press release includes non-GAAP metrics: adjusted revenue growth, adjusted constant currency revenue growth, and adjusted diluted EPS. Adjusted revenue excludes an increase in reserves tied to Italy’s medical device “payback” measure following a recent court ruling. Adjusted diluted EPS excludes, as applicable, restructuring and rationalization, impairment, acquisition/integration/divestiture items, separation costs for the RemainCo/NewCo plan, pension termination charges, EU MDR registration costs, intangible amortization, ERP implementation and related IT transition costs, tax adjustments, and dilutive shares impact.
The information is furnished, not filed, and is not incorporated by reference unless expressly stated. Exhibits include the earnings release (99.1) and conference call slides (99.2).
Teleflex (TFX) received an amended Schedule 13G/A from BlackRock, Inc. reporting beneficial ownership of 5,158,480 shares of common stock, representing 11.7% of the class as of 09/30/2025. BlackRock reports sole voting power over 5,053,017 shares and sole dispositive power over 5,158,480 shares, with no shared voting or dispositive power.
BlackRock certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes that iShares Core S&P Small-Cap ETF holds an interest in Teleflex common stock that is more than five percent of outstanding shares.
Janus Henderson Group plc is disclosed as a beneficial owner of Teleflex Incorporated common stock, reporting an aggregate 4,149,271 shares representing 9.4% of the class. The filing indicates no sole voting or dispositive power and instead reports shared voting and dispositive power over the reported shares.
The Janus Henderson Enterprise Fund is shown holding 2,885,870 shares (6.5%) with shared voting and dispositive power. The filing includes a certification that the shares were acquired and are held in the ordinary course of business and not to influence control. The document is signed by Kristin Mariani and contains a power of attorney authorizing certain officers to execute ownership filings.
Teleflex Inc. (TFX) Form 4: Director Stuart A. Randle executed an open-market purchase of 1,000 common shares on 08/05/2025 at a weighted-average price of $115.86 (trade range $115.53–$116.06). The transaction is coded “P,” confirming it was a direct–purchase rather than an option exercise or gift. After the buy, Randle’s direct ownership rises to 7,547 shares, an increase of roughly 15% in his personal stake.
No derivative securities were involved and there were no dispositions. Insider buying—especially by an independent director—can serve as a modest positive signal of management confidence and alignment with shareholder interests, though the dollar value (~$116k) is not large relative to Teleflex’s market capitalization.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
